Biotech

All Articles

TPG leadings up funds to $580M for investments throughout life scientific researches

.Property manager TPG, which has sustained biotechs such as Sionna Therapies as well as Santa Ana Bi...

Merck ceases phase 3 TIGIT trial in lung cancer cells for futility

.Merck &amp Co.'s TIGIT system has actually gone through yet another trouble. Months after shutterin...

After a difficult year, Exscientia folds up right into Recursion

.After a year defined by pipe hairstyles, the departure of its own CEO and layoffs, Exscientia will ...

Cullinan, after $25M offer, restore bispecific to Port

.Cullinan Therapy was actually thrilled sufficient along with Port BioMed's bispecific immune system...

A nearer take a look at Tough Biotech's Ferocious 15

.Within this full week's episode of "The Top Line," our experts're diving into Strong Biotech's annu...

Lilly experiences period 2 failing of tau-targeting med

.The confetti is actually still soaring coming from Eli Lilly's celebration commemorating the approv...

Biogen CMO Maha Radhakrishnan participates in Sofinnova-- Chutes &amp Ladders

.Accept to today's Chutes &amp Ladders, our roundup of considerable management hirings, shootings as...

Lykos will definitely ask FDA to rethink its decision following being rejected of MDMA treatment for trauma

.Complying with an unsatisfactory presenting for Lykos Rehabs' MDMA prospect for trauma at a latest ...

AN 2 fifty percents headcount, ceases period 3 trial after records disappoint

.AN2 Rehabs is actually reassessing its own service in feedback to lackluster midphase data, pledgin...

Merck spends $700M for bispecific, spying autoimmune position and possibility to test Amgen in cancer cells

.Merck &amp Co. is paying $700 million upfront to test Amgen in a blood cancer cells market. The dea...